stoxline Quote Chart Rank Option Currency Glossary
  
MacroGenics, Inc. (MGNX)
14.72  -0.24 (-1.6%)    03-28 16:00
Open: 14.74
High: 15.2525
Volume: 771,111
  
Pre. Close: 14.96
Low: 14.285
Market Cap: 913(M)
Technical analysis
2024-03-28 4:52:53 PM
Short term     
Mid term     
Targets 6-month :  22.07 1-year :  25.55
Resists First :  18.9 Second :  21.87
Pivot price 15.68
Supports First :  14.07 Second :  11.71
MAs MA(5) :  14.55 MA(20) :  16.88
MA(100) :  12.38 MA(250) :  8.24
MACD MACD :  -0.7 Signal :  -0.3
%K %D K(14,3) :  7.2 D(3) :  5
RSI RSI(14): 40.2
52-week High :  21.87 Low :  4.28
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MGNX ] has closed above bottom band by 26.7%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.3 - 15.38 15.38 - 15.45
Low: 14.03 - 14.15 14.15 - 14.24
Close: 14.55 - 14.72 14.72 - 14.86
Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Headline News

Thu, 28 Mar 2024
MacroGenics (NASDAQ:MGNX) Stock Price Down 3.6% - MarketBeat

Fri, 22 Mar 2024
Exchange Traded Concepts LLC Boosts Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World

Thu, 14 Mar 2024
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results - Yahoo Finance

Thu, 07 Mar 2024
MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript - Seeking Alpha

Thu, 07 Mar 2024
Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 62 (M)
Shares Float 52 (M)
Held by Insiders 2.6 (%)
Held by Institutions 100 (%)
Shares Short 5,020 (K)
Shares Short P.Month 8,340 (K)
Stock Financials
EPS -0.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.46
Profit Margin -15.5 %
Operating Margin -460.4 %
Return on Assets (ttm) -36.4 %
Return on Equity (ttm) -6.2 %
Qtrly Rev. Growth -85.4 %
Gross Profit (p.s.) 0
Sales Per Share 0.94
EBITDA (p.s.) -2.55
Qtrly Earnings Growth 0 %
Operating Cash Flow -78 (M)
Levered Free Cash Flow -25 (M)
Stock Valuations
PE Ratio -98.14
PEG Ratio 0
Price to Book value 5.98
Price to Sales 15.64
Price to Cash Flow -11.76
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android